Medigus Closes $8.4 Million Underwritten Public Offering of American Depositary Shares
Medigus Ltd. announced the closing of an underwritten public offering of 3,659,735 American Depositary Shares (ADSs) at $2.30 each, raising approximately $8.4 million in gross proceeds. The funds are intended for working capital and general corporate purposes. The underwriter holds a 15% option to purchase additional ADSs, potentially increasing gross proceeds to about $9.6 million. This offering is conducted under an effective registration statement with the SEC.
- Gross proceeds of approximately $8.4 million raised from the offering.
- Intended use of funds includes working capital and general corporate purposes.
- Potential to raise up to $9.6 million if the underwriter exercises the over-allotment option.
- Possible dilution of shares if the underwriter exercises the full over-allotment option.
OMER, Israel, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq, TASE: MDGS) (“Medigus” or “the Company”), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced the closing of an underwritten public offering of 3,659,735 American Depositary Shares (the “ADSs”). Each ADS was sold to the public at a price per ADS of
The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
The Company has also granted the underwriter an option to purchase an additional 15 percent of the ADSs offered in the public offering solely to cover over-allotments, if any, exercisable until the earlier of 30-days or the last day of trading of the Company’s ordinary shares on the Tel-Aviv Stock Exchange prior to their delisting which would increase the total gross proceeds of the offering to approximately
Aegis Capital Corp. acted as sole bookrunner for the offering.
This offering was made pursuant to an effective registration statement on Form F-3 (No 333-238162) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on May 15, 2020. A final prospectus describing the terms of the proposed offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov.
Electronic copies of the final prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medigus
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the Company's advanced technology, please visit www.medigus.com.
Cautionary Note Regarding Forward Looking Statements
This press release may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of the Medigus’ management and its knowledge of the relevant market. Medigus has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. For example, Medigus uses forward looking statements when describing the proposed use of proceeds. These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved, due to inter alia the spread of COVID-19 as well as the restriction deriving therefrom. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of Medigus activity to differ significantly from the content and implications of such statements. Other risk factors affecting Medigus are discussed in detail in Medigus’ filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and Medigus undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither Medigus nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Medigus’ securities. Nothing in this press release should be deemed to be medical or other advice of any kind.
Investor Contact
Tatiana Yosef
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
FAQ
What are the details of Medigus' public offering?
How does Medigus plan to use the proceeds from the offering?
What is the total potential gross proceeds from Medigus' offering?
What is the impact of the offering on Medigus shareholders?
Who acted as the underwriter for Medigus' public offering?
